Your browser is no longer supported. Please, upgrade your browser.
Settings
MDVN Medivation, Inc. daily Stock Chart
MDVN [NASD]
Medivation, Inc.
Index- P/E39.59 EPS (ttm)1.43 Insider Own1.10% Shs Outstand164.63M Perf Week-4.81%
Market Cap9.32B Forward P/E25.79 EPS next Y2.20 Insider Trans-5.62% Shs Float162.49M Perf Month-6.13%
Income252.70M PEG1.13 EPS next Q0.31 Inst Own92.40% Short Float1.84% Perf Quarter46.09%
Sales996.60M P/S9.35 EPS this Y-11.10% Inst Trans-0.88% Short Ratio0.84 Perf Half Y18.04%
Book/sh5.48 P/B10.33 EPS next Y68.33% ROA21.50% Target Price64.06 Perf Year0.81%
Cash/sh- P/C- EPS next 5Y35.15% ROE34.00% 52W Range26.41 - 62.94 Perf YTD17.11%
Dividend- P/FCF31.00 EPS past 5Y50.90% ROI27.10% 52W High-8.87% Beta0.91
Dividend %- Quick Ratio4.20 Sales past 5Y72.10% Gross Margin- 52W Low117.19% ATR1.22
Employees628 Current Ratio4.20 Sales Q/Q41.30% Oper. Margin40.20% RSI (14)37.50 Volatility2.04% 1.95%
OptionableYes Debt/Eq0.00 EPS Q/Q243.60% Profit Margin25.40% Rel Volume0.51 Prev Close56.61
ShortableYes LT Debt/Eq0.00 EarningsAug 04 AMC Payout0.00% Avg Volume3.55M Price57.36
Recom2.00 SMA20-3.71% SMA50-2.29% SMA20026.47% Volume1,331,178 Change1.32%
May-06-16Upgrade Citigroup Neutral → Buy
May-06-16Reiterated Barclays Overweight $48 → $70
May-05-16Reiterated Maxim Group Buy $47 → $76
May-02-16Reiterated Stifel Buy $52 → $66
May-02-16Reiterated Jefferies Hold $39 → $52
Apr-29-16Reiterated Wedbush Outperform $47 → $59
Apr-06-16Initiated Sun Trust Rbsn Humphrey Buy $56
Mar-31-16Reiterated Credit Suisse Outperform $48 → $49
Mar-30-16Initiated Goldman Neutral
Feb-19-16Initiated BofA/Merrill Buy
Feb-01-16Reiterated Wedbush Outperform $59 → $47
Jan-27-16Downgrade Canaccord Genuity Buy → Hold $90 → $45
Jan-21-16Initiated Credit Suisse Outperform
Nov-10-15Reiterated Maxim Group Buy $74 → $54
Nov-09-15Reiterated RBC Capital Mkts Sector Perform $50 → $40
Nov-06-15Reiterated UBS Buy $74 → $68
Nov-06-15Reiterated RBC Capital Mkts Sector Perform $50 → $40
Sep-28-15Reiterated Maxim Group Buy $171 → $74
Sep-16-15Initiated Nomura Buy
Sep-03-15Initiated Citigroup Neutral
Jun-28-16 09:46AM  Faber Report: M&A updates
Jun-27-16 04:32PM  MEDIVATION, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Se
11:03AM  Medivation, Inc. breached its 50 day moving average in a Bearish Manner : MDVN-US : June 27, 2016
07:00AM  Medivation Voted Top Workplace in San Francisco Bay Area for Fourth Year in a Row Marketwired
04:51AM  Sanofi to Exit Animal Care in $25 Billion Asset Swap With Boehringer
Jun-24-16 04:18PM  MEDIVATION, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
02:19PM  Glass Lewis urges Medivation shareholders to support current board
08:30AM  Glass Lewis Recommends Medivations Stockholders Support the Companys Current Board Business Wire
Jun-23-16 05:50PM  Medivation Sends Letter to Stockholders to Set the Record Straight on Sanofis Misleading Claims Business Wire
05:01PM  Sanofi's Likely Sweetener for Medivation Panned
04:00PM  2 Words That Could Bring Down the Entire Prescription Drug Industry at Motley Fool
09:24AM  $18,543 Invested in This Biotech a Decade Ago Is Now Worth $1 Million at Motley Fool
08:56AM  The Market In 5 Minutes: It's Brexit Time
Jun-22-16 01:46PM  Sanofi Said to Consider Adding Future Payments to Medivation Bid at Bloomberg
Jun-20-16 06:25PM  NIH won't cut price of taxpayer-funded prostate cancer drug
Jun-17-16 12:25PM  BioMarin Takeout Rumors Swirl, Industry Insiders Aren't Convinced
09:56AM  Medivation's (MDVN) Pidilizumab Positive in Phase I/II Study
Jun-16-16 07:00AM  Medivation's Pidilizumab Shows Potential Clinical Benefit and Safety in Children With Diffuse Intrinsic Pontine Glioma (DIPG) Marketwired
Jun-14-16 08:30PM  MEDIVATION INVESTIGATION ALERT Andrews & Springer LLC Is Investigating Medivation, Inc. For Potential Breaches of Fiduciary Duty - MDVN Business Wire
09:00AM  Medivation Has a Good Case for Patience at Bloomberg
Jun-13-16 05:32PM  MEDIVATION, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
05:01PM  Medivation Urges Shareholders to Reject Sanofi Proposal
12:50PM  UPDATE 1-Sanofi, Medivation advance to next phase of takeover fight Reuters
09:33AM  Sanofi files request to replace Medivation board Reuters
09:28AM  Sanofi to Approach Medivation Shareholders to Replace Board at Bloomberg
08:39AM  Medivation Files Definitive Consent Revocation Statement and Mails Letter to Stockholders Business Wire
08:07AM  MEDIVATION (MDVN) SHAREHOLDER ALERT Andrews & Springer LLC Is Investigating Medivation, Inc. For Potential Breach of Fiduciary Duty Business Wire
Jun-10-16 07:42AM  The Ingenious Moneymaking Method of the World's Super Investors: Buffett, Lynch, Icahn
Jun-08-16 07:37AM  Sanofi hopes to oust Medivation's board by August 1
Jun-07-16 01:44PM  Valeant's Share Price Tumbles, Even as Papa Reiterates Plans for Divestitures
Jun-06-16 03:45PM  SEC Issues Charges on Pharma Insider Trading
06:05AM  MEDIVATION, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Jun-03-16 09:30AM  Redmile Group Sticking With Healthcare Picks After Rough Q1 at Insider Monkey
Jun-02-16 01:30PM  What Will It Take for Sanofi to Snag Medivation? $63 a Share at Barrons.com
07:35AM  Medivation Pulls Up Shareholder Drawbridge as Sanofi Battle Looms
07:00AM  Medivation and Astellas Initiate Phase III Trial of Enzalutamide in Patients With Triple-Negative Breast Cancer Marketwired
07:00AM  Astellas and Medivation Initiate Phase III Trial of Enzalutamide in Patients with Triple-Negative Breast Cancer PR Newswire
06:03AM  MEDIVATION, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
02:53AM  Medivation sets eligibility date for shareholder consent on board revamp
02:52AM  UPDATE 1-Medivation sets eligibility date for shareholder consent on board revamp
12:01AM  Medivations Drug for Stubborn Cancers Raises Its Allure at Bloomberg
Jun-01-16 07:28PM  Medivation sets June 1 deadline for shareholder consent on board revamp
06:45PM  Medivation Sets Record Date for Sanofis Proposed Consent Solicitation Business Wire
05:57PM  Sanofi Asks for Record Date for Vote on Medivation's Board at The Wall Street Journal
03:19PM  Sanofi requests Medivation set deadline for shareholder consent on board revamp
09:39AM  Bayer, Monsanto have yet to engage in meaningful dialogue...
May-31-16 05:58PM  What Happened to Ioniss Revenues in 1Q16?
May-28-16 12:15AM  [$$] Medivations Sanofi Strategy May Be in Trouble at The Wall Street Journal
May-27-16 08:05PM  [$$] Medivation May Feel Pressured by Sanofi at The Wall Street Journal
04:28PM  MEDIVATION, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
01:20PM  Dealpolitik: Medivation's 'Just Say No' Strategy May Be in Trouble at The Wall Street Journal
11:46AM  Medivation Fires Back Following Sanofi's Board Proposal
10:01AM  Interested in Medivation? Take a Number! at Motley Fool
08:33AM  Delayed FDA Decision Sends Sarepta Therapeutics Soaring
08:08AM  Medivation Files Preliminary Consent Revocation Statement Business Wire
May-26-16 01:38PM  Could Rally Cool Off Ahead Of Friday's GDP Data and Yellen Speech?
11:35AM  How Medivation Shareholders May Lose Big by Poison Pill in Hostile Takeover Fight With Sanofi at 24/7 Wall St.
10:34AM  Please Gilead, Celgene and Amgen. Don't Buy Medivation. at Barrons.com
10:23AM  5 stocks to watch at MarketWatch
10:20AM  Sanofi's Diabetes Drug Combination Wins FDA Panel Backing
02:25AM  PRESS DIGEST- New York Times business news - May 26 Reuters
12:12AM  [$$] Sanofi Moves to Replace Medivation Board at The Wall Street Journal
May-25-16 05:39PM  Sanofi Just Went Hostile in Its Medivation Takeover Bid at Fortune
04:59PM  Medivation: Three Biotech Giants Enter. Which One Leaves? at Barrons.com
04:33PM  Sanofi moves to oust Medivation board in $9.3 bln takeover fight Reuters
04:16PM  MEDIVATION, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:10PM  Medivation to Present at the Following Conferences Marketwired
04:08PM  Sanofi Moves To Replace Medivations Board As New Buyers Rumored
01:59PM  [$$] Sanofi Moves to Replace Medivation Board at The Wall Street Journal
01:17PM  Heres Why Medivation Inc (MDVN) Is in Spotlight Today at Insider Monkey
01:07PM  [$$] Sanofi seeks to oust entire Medivation board at Financial Times
12:38PM  Why Sanofi SA (ADR) (SNY) Is Trending on Wednesday at Insider Monkey
12:23PM  European Markets End in Positive Territory; Rally for Second Day
12:02PM  Sanofi Plays Game of Chicken With Medivation at Bloomberg
11:31AM  Pfizer Wants to Be Seen as an Oncology Powerhouse
11:00AM  Sanofi wants to dump Medivation's board after rejected deal
10:48AM  Medivation Advises Its Shareholders To Spurn Sanofi's Move To Replace Entire Board
10:24AM  Sanofi Moves to Oust Medivation Board
09:28AM  The Market In 5 Minutes: Bold Moves
08:46AM  Medivation Urges Stockholders to Reject Sanofis Attempt to Replace Medivation Board of Directors Business Wire
08:23AM  Celgene, Gilead Said to Join Suitors Mulling Medivation Bids at Bloomberg
07:19AM  Sanofi Seeks to Change Medivation Board as Advances Spurned at Bloomberg
06:58AM  Sanofi names eight candidates to replace Medivation board
06:01AM  May 25 Premarket Briefing: 10 Things You Should Know
12:37AM  Exclusive: Sanofi to unveil challenge to Medivation's board - sources
May-23-16 07:00AM  Arm of I-SPY 2 TRIAL Investigating Medivation's Talazoparib for Treatment of Breast Cancer Activated Marketwired
May-21-16 09:40AM  Here's What Pfizer's Telling Us About Biotech M&A at Motley Fool
May-20-16 12:07PM  A Scarcity of Biotech Assets for Buyouts? at Barrons.com
09:30AM  The Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase
May-19-16 03:36PM  Biotech Stock Roundup: Pfizer to Buy Anacor for $5.2B, Pipeline Setbacks for Aduro, Trevena
May-17-16 03:06PM  Medivation: Xtandi Global Sales Rose 53% in 1Q16
08:13AM  Pfizer to Buy Anacor, Add Eczema Treatment to Portfolio Zacks
06:07AM  MEDIVATION, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
May-16-16 01:05PM  Pfizer to buy Peninsula drug developer for $5.2 billion in latest Bay Area M&A at American City Business Journals
11:57AM  Pfizer Beats Allergan to Eczema Drugmaker Anacor for $5.2B at TheStreet
10:06AM  What Do Analysts Recommend for Medivation?
May-13-16 06:07PM  Medivation Is for Sale: How Much Should It Get?
05:46PM  Medivation Shares Stand Pat Amid Further Bid Speculation at TheStreet
05:06PM  Sanofi Is Moving to Replace Medivations Entire Board in Takeover Bid at Fortune
11:55AM  Sanofi presses on with threat to oust Medivation's board
Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of medical therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (CRPC) patients. The company also develops Enzalutamide, which is in phase III clinical trials for the treatment of non-metastatic CRPC, and metastatic and non-metastatic hormone sensitive prostate cancer; and phase II clinical trials for the treatment of hepatocellular carcinoma, androgen receptor positive (AR+) triple negative breast cancer, estrogen receptor positive or progesterone receptor positive and human epidermal growth factor receptor 2 (HER2) normal breast cancer, and AR+ HER2 amplified breast cancer. In addition, it develops Talazoparib, which is in phase II clinical trials for treatment of germline mutated HER2 normal breast cancer; Pidilizumab that is in phase II clinical trials for the treatment of relapsed or refractory diffuse large B-cell lymphoma; and MDV4463, which is in phase I clinical trials for the treatment of nonalcoholic steatohepatitis. The company has collaboration agreement with Astellas Pharma, Inc. for the development, manufacture, and commercialization of XTANDI; and License and Manufacturing and supply agreement with CureTech, Ltd. for the development, manufacture, and commercialization of biologic molecules. Medivation, Inc. is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Powell Andrew Kenneth WilliamSVP, General Counsel & Crp SecJun 06Sale60.422,578155,76328,517Jun 06 08:10 PM
Bierly RickCFO (former)May 06Sale60.126,315379,63728,744May 09 05:35 PM
Bierly RickCFO (former)May 05Sale59.204,025238,28035,059May 09 05:35 PM
Svoronos DawnDirectorMar 14Sale38.906,000233,40018,234Mar 16 05:06 PM
Hirmand MohammadInterim Chief Medical OfficerMar 04Sale41.101,52562,68539,342Mar 07 08:44 PM
Bierly RickChief Financial OfficerMar 04Sale40.002,998119,92039,084Mar 07 08:43 PM
Hung DavidPresident and CEOFeb 04Sale31.186,350197,9931,504,654Feb 05 07:05 PM
Machado Clarence PatrickDirectorJan 19Option Exercise3.3775,000252,525141,156Jan 21 05:45 PM
Machado Clarence PatrickDirectorJan 19Sale37.3475,0002,800,56266,156Jan 21 05:45 PM
Lobacki Joseph MChief Commercial OfficerJan 04Sale46.503,065142,52319,365Jan 05 06:14 PM
VERNON W ANTHONYDirectorDec 14Buy40.6915,000610,35028,704Dec 16 05:40 PM
Hung DavidPresident and CEODec 03Sale43.1010,950471,9661,511,004Dec 04 04:36 PM
Hirmand MohammadInterim Chief Medical OfficerDec 03Sale43.401,07546,65531,113Dec 04 04:35 PM
Hirmand MohammadInterim Chief Medical OfficerNov 09Sale41.912329,72232,188Nov 12 06:46 PM
Svoronos DawnDirectorSep 08Sale89.153,100276,36512,117Sep 08 07:39 PM